BRAIN-2 COVID-19 Administrative Supplement

NIA资助的Brain-ICU-2研究[揭示了神经心理学的危险因素和发病率 ICU幸存者的功能障碍(痴呆)，第二项研究]将确定ICU精神错乱和 痴呆症。对Brain-ICU-2研究(R01 AG58639)的拟议行政补充是对 NIA提供2019年冠状病毒疾病行政补充和修订补充 (新冠肺炎)(非-AG-022；PA-18-591)。急性精神分裂症所致脑组织损害的认识 SARS冠状病毒2(SARS-CoV-2)，我们将进行新的神经病理检查 对受新冠肺炎影响的危重患者以及阿尔茨海默病和相关患者的研究 有/没有危重疾病的痴呆症(ADRD)。通过学习新冠肺炎，我们将更好地理解两国关系 在精神错乱和ADRD之间。在当前的新冠肺炎大流行期间，全世界的重症监护病房(ICU) 全国各地都有经历精神错乱的患者，这是未来ADRD的一个主要风险因素。这些精神错乱 意识受损的症状包括头痛、味觉、嗅觉和视觉功能的改变， 神经病、癫痫、躁动、脑炎和/或格林-巴利综合征。这些精神错乱的迹象和 症状可能是由于脑部感染SARS-CoV-2，特别是那些患有ADRD的人。我们不会 了解新冠肺炎是否有直接的神经系统后果(例如，炎症)，和/或间接的 神经系统后果，例如，凝血障碍。据我们所知，有限的尸检系列包括 脑组织已经发表。没有提供有关ADRD的信息。拟议的补编将 具体比较多组患者，ICU患者有/没有ADRD，有/没有新冠肺炎，沿着 有无ADRD和有/无新冠肺炎的非ICU患者。Brain-ICU-2研究将为ICU提供 有/无ADRD伴/不伴新冠肺炎的患者。NIA支持的宗教秩序研究(ROS；第30页 AG10161、R01 AG15819)和Rush Memory and Aging Project(MAP；R01 AG17917)将提供非ICU 有/无ADRD和有/无新冠肺炎的患者。拟议的补编将在以下基础上进一步发展 Vanderbilt和Rush Brain-ICU-2研究团队之间的合作，并代表了 新冠肺炎脑与非新冠肺炎脑的综合神经病理学检查 有/没有ADRD，以及有/没有危重疾病。本补充资料将为 全球新冠肺炎研究界，对重症监护病房精神错乱领域产生了强大和持续的影响 还有阿德勒。

The NIA-funded BRAIN-ICU-2 Study [Bringing to light the Risk factors And Incidence of Neuropsychological dysfunction (dementia) in ICU Survivors, 2nd Study] will define the relationship between ICU delirium and dementia. The proposed administrative supplement to BRAIN-ICU-2 Study (R01 AG58639) is in response to NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) (NOT-AG-022; PA-18-591). To understand the brain tissue damage of acute delirium caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), we will perform new neuropathological studies of critically ill patients affected by COVID-19, as well as those with Alzheimer’s disease and related dementia (ADRD) with/without critical illness. By studying COVID-19, we will better understand the relationship between delirium and ADRD. During the current COVID-19 pandemic, intensive care units (ICU’s) across the nation are awash with patients experiencing delirium, a major ICU risk factor for future ADRD. These delirium symptoms of impaired consciousness include headache, alteration of gustatory, olfactory, and visual function, neuropathy, seizures, agitation, encephalitis, and/or Guillain-Barre syndrome. These delirium signs and symptoms could be due to SARS-CoV-2 infection of the brain, particularly in those with ADRD. We do not know if there are direct nervous system consequences of COVID-19 (e.g., inflammation), and/or indirect nervous system consequences, e.g., coagulopathy. To our knowledge, limited autopsy series that included brain tissue have been published. No information about ADRD was provided. The proposed supplement will specifically compare multiple groups of patients, ICU patients with/without ADRD with/without COVID-19, along with non-ICU patients with/without ADRD and with/without COVID-19. The BRAIN-ICU-2 study will provide ICU patients with/without ADRD with/without COVID-19. The NIA-supported Religious Orders Study (ROS; P30 AG10161, R01 AG15819), and Rush Memory and Aging Project (MAP; R01 AG17917) will provide non-ICU patients with/without ADRD and with/without COVID-19. The proposed supplement will further build on collaboration between the Vanderbilt and Rush BRAIN-ICU-2 study teams, and represent the most comprehensive neuropathologic examination of COVID-19 brains compared to non-COVID-19 brains, in those with/without ADRD, and with/without critical illness. This supplement will create a unique resource for the world-wide COVID-19 research community, with a strong and sustained impact on the fields of ICU delirium and ADRD.